NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/12/2023
Voltar para busca
Dado oficial do USPTO
THERAMEX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
18
Atualização mais recente
05/12/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
08/09/2022
Data de registro
05/12/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/12/2023
Última transação
05/12/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
3
Tipo de titular
99
Localização do titular
Belgravia, London, GB
Examinador
BERNS, LEE ANNE
Unidade examinadora
M90
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the term 'THERAMEX' to the right of a lady figure.
Titulares e representantes
Titulares
Theramex HQ UK Limited
Representantes
Leigh Ann Lindquist SUGHRUE MION, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-fungal pharmaceutical preparations; Contraceptive preparations; contraceptive sponges; chemical contraceptives; oral contraceptives; Dermatological pharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations and substances for use in relation to women's healthmenopauseosteoporosisuterine fibroidsendometriosisadenomyosismenstrual bleeding disordersfertilityinfertilityassisted reproductive technologyIVF; Pharmaceutical preparations and substances containing steroids; Pharmaceutical preparations and substances containing hormones; Pharmaceutical preparations and substances in the nature of hormone replacement therapy; pharmaceutical preparations and substances for use in relation to reproductive healthcontraceptionmenstrual bleeding disordersfertilityinfertilityfertility enhancement preparationsassisted reproductive technologyIVFmiscarriage; pharmaceutical preparations and substances for use in relation to contraception; pharmaceutical preparations and substances for use in relation to conceptioncontraceptionmenstrual bleeding disordersfertilityinfertilityfertility enhancement preparationsassisted reproductive technologyIVFmiscarriage; pharmaceutical preparations and substances for use in relation to fertility; fertility enhancement preparations; pharmaceutical preparations and substances for use in relation to the treatment of infertility; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for use in dermatology; Pharmaceutical preparations for the treatment of menopause; Pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; Pharmaceutical preparations and substances for the treatment of osteoporosis; Pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; Pharmaceutical preparations and substances for the treatment of cartilage disorders; Pharmaceutical preparations and substances for the treatment of bone disorders; Pharmaceutical preparations and substances for the treatment of bone loss; Pharmaceutical preparations and substances for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of calcium deficiency; Pharmaceutical preparations and substances being calcium regulators; Pharmaceutical preparations and substances for the treatment of Paget's disease; Phosphates for pharmaceutical purposes; Self-injectors sold filled with pharmaceutical preparations for the treatment of infertility for subcutaneous injectionosteoporosis; Vitamin supplements; mineral supplements; calcium supplements; all the above being for human use and none being for dental use or for use in relation to oral hygiene
Publicações
Histórico de despachos e eventos da marca no USPTO.
18 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
05/12/2023
ISPO
WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
21/09/2023
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
20/09/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/09/2023
PUBO
PUBLISHED FOR OPPOSITION
19/09/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/08/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/07/2023
GNRT
NON-FINAL ACTION E-MAILED
06/07/2023
CNRT
NON-FINAL ACTION WRITTEN
06/07/2023
DOCK
ASSIGNED TO EXAMINER
22/06/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
27/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/09/2022
NWAP
NEW APPLICATION ENTERED
12/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace THERAMEX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.